About AnGes
About AnGes
Top Message
Values
Mission
Business Area
Business Model
Company Profile
Board of Directors
Locations
History
Group
Alliance Status
Pipeline
Pipeline
Main pipeline products
Product for HGF gene therapy
NF-κB Decoy Oligo DNA
Vaccine
Global Alliance
Global Alliance
EmendoBio, Inc.
MyBiotics Pharma Ltd.
ACRL
Investor Relations
Investor Relations
IR News
Stock Performance
Financial Reports
Intellectual Property Reports
Other Information Materials
Analyst Report
IR STREET(IR related information)
IR STREET(Email Alerts)
Corporate Brochure
Contact us
COVID-19
Contact us
Site Policy
Privacy Policy
JP
EN
Leading Global in Gene Medicine
About AnGes
News
All
Development
Product Info
IR
Information
2023.11.29
IR
Notice on the progress of domestic Phase II clinical trials of NF-κB decoy oligo DNA for the treatment of chronic intervertebral disc low back pain
2023.11.15
IR
Vasomune and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB of the AV-001 Phase 2a Study
2023.11.08
IR
Consolidated Financial Report for the Third Quater 2023
2023.10.18
IR
Notice Regarding the Start of Administration of NF-κB Decoy Oligo DNA for the Treatment of Chronic Intervertebral Disc Lumbago in a Phase II Clinical Trial in Japan
2023.08.09
IR
Consolidated Financial Report for the Second Quater 2023
Learn more
Pipeline
Learn more
Global Alliance
Learn more
Contact us